Ranolazine treatment in the heterogeneous symptomatic stable coronary artery disease population

J Cardiovasc Med (Hagerstown). 2018 Apr;19(4):186-190. doi: 10.2459/JCM.0000000000000627.

Authors

Mauro Borzi^{1

2}, Alfredo Intorcia¹, Marco A Perrone¹, Giulia Grilli¹, Domenico Sergi¹, Martina Borzi¹, Francesco Romeo¹

Affiliations

¹ Department of Cardiovascular Disease, University of Rome Tor Vergata, Rome, Italy.
² Faculty of Medicine and Surgery, Catholic University Our Lady of Good Counsel, Tirana, Albania.

PMID: 29432398
DOI: 10.2459/JCM.0000000000000627

No abstract available

Publication types

Letter

MeSH terms

Aged
Angina Pectoris / drug therapy*
Coronary Angiography
Coronary Artery Disease / complications
Coronary Artery Disease / physiopathology*
Female
Humans
Male
Middle Aged
Quality of Life
Ranolazine / administration & dosage*
Self Report
Sodium Channel Blockers / administration & dosage*
Treatment Outcome

Substances

Sodium Channel Blockers
Ranolazine